Navigation Links
Researchers Find Link Between Organ Transplants, Cancer
Date:7/16/2008

Immune-suppressing drugs may trigger protein that boosts tumor growth, study finds

WEDNESDAY, July 16 (HealthDay News) -- Anti-rejection drugs given after organ transplants may be the reason why 15 percent to 20 percent of individuals who receive such transplants have a higher risk of developing cancer within the next decade.

The good news is that targeted therapies could diminish the risk, said Harvard researchers reporting in the July 15 issue of Cancer Research.

The tumors themselves may have already existed before the transplant procedure or they may be a return of an old cancer. An immune system dampened by immunosuppressive drugs could make it easier for both scenarios to take place. On the other hand, a virus introduced from the donor organ may have precipitated the cancer, the researchers said.

And heightened production of vascular endothelial growth factor (VEGF) after the transplant may also be a factor. While this protein facilitates essential blood flow to the new organ, it can also promote the formation of new blood vessels which feed tumor growth, according to the researchers.

"It may be that anti-VEGF agents given judiciously after transplantation can reduce future cancer occurrence," said study senior author Soumitro Pal, assistant professor at Harvard Medical School's Transplantation Research Center at Children's Hospital in Boston, in a news release from the American Association for Cancer Research. "... Once the organ has stabilized, it may be possible to lower the level of VEGF expression to prevent tumor growth. We would need to figure out how to balance benefit and risk to keep cancer at bay."

Pal and his colleagues implanted human kidney cancer cells into mice, then gave the rodents cyclosporine, an immunosuppressant drug often used after transplants. Mice that received the drug grew tumors at a faster rate than mice left untreated.

But the researchers also found a potential solution to the problem: Giving targeted anti-VEGF therapy reduced the pace of growth.

Cyclosporine seems to promote the growth of cancer by activating different forms of protein kinase C, which, in turn, stimulates VEGF production, the researchers said.

More information

For more on organ and tissue donation, visit organdonor.gov.



-- HealthDay Staff



SOURCE: American Association for Cancer Research, news release, July 15, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Tufts researchers discover link between DNA palindromes and disease
2. Researchers hone technique to KO pediatric brain tumors
3. Researchers link Huntingtons disease to overactive immune response in the brain
4. Researchers: Program discourages HIV transmission in Russia
5. Stanford Bio-X researchers use needle-thin probe to get first look at working muscle fiber
6. Researchers design model for automated, wearable artificial kidney
7. Researchers Gather to Address New Tools in Development for Breast Cancer Detection
8. Some drugs increase risk of falling: UNC researchers
9. HIV prevention researchers to compare common ARV as a pill and vaginal gel in unique study
10. Jefferson researchers show antibody to breast cancer-secreted protein blocks metastasis
11. Wake Forest researchers say popular fish contains potentially dangerous fatty acid combination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Kennett Square, PA (PRWEB) , ... March 23, 2017 , ... ... sunny days. That means many students are thinking about summer internships , which ... (or lack thereof). , The pros at Garden Media Group, a boutique public relations ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... products at competitive pricing. Verisys through its FACIS and other ... restrictions and Disciplinary actions. , “We are delighted to be able to offer ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... stands with all Americans facing life-altering and fatal diseases in opposition to the ... shortsighted decisions that would eviscerate care, services, and hope for the most vulnerable ...
(Date:3/23/2017)... ... March 23, 2017 , ... On ... Dagger Foundation the US Special Operations Command’s Patriot Award. The award was presented ... thanked Task Force Dagger Foundation for its significant and enduring support to the ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... The Boulevard ... 10am - 2pm. All events will be located in the Main West Entrance ... a no-cost Child ID event. No appointment is necessary and each child with a ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... Md. , March 23, 2017  The U.S. ... Bavencio (avelumab) for the treatment of adults and pediatric ... carcinoma (MCC), including those who have not received prior ... MCC, a rare, aggressive form of skin cancer. ... common cancers, patients with a rare form called Merkel ...
(Date:3/23/2017)... VANCOUVER, British Columbia , March 23, ... ) (the "Company" or "Sophiris"), a clinical late-stage biopharmaceutical ... diseases, today announced that data from its successful Phase ... a focal treatment for localized prostate cancer, will be ... the 32 nd Annual European Association of Urology ...
(Date:3/23/2017)... -- Research and Markets has announced the addition of ... their offering. ... The global oxygen therapy devices market to grow at a CAGR ... Global Oxygen Therapy Devices Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
Breaking Medicine Technology: